Trial Profile
A Retrospective and Prospective Non-interventional Open Label Study to Assess the Real Life of Treatment-naive Patients With Wet Age-related Macular Degeneration in Routine Clinical Practice in France and Starting an Anti VEGF Therapy With Aflibercept
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Apr 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms RAINBOW
- Sponsors Bayer
- 01 Apr 2023 Results(n=516) assessing IVT-AFL effectiveness, treatment patterns, and safety in patients with nAMD in France published in the Graefes Archive for Clinical and Experimental Ophthalmology
- 02 Jul 2019 Status changed from active, no longer recruiting to completed.
- 07 Jun 2019 Planned primary completion date changed from 26 May 2019 to 15 Jun 2019.